invIOs
invIOs is a biotech company focused on developing next-generation cancer therapeutics, leveraging immune system activation to create personalized and targeted treatments against solid tumors. Their mission is to transform patients' lives with innovative, sustainable technologies, aiming to become a leading global biotech provider of individualized cancer treatments.
Industries
Nr. of Employees
small (1-50)
Products
Autologous cell therapy product targeting Cbl‑b (clinical-stage)
An autologous peripheral blood cell therapy in which immune cells are modified to silence the checkpoint regulator Cbl‑b, intended to activate patient immune responses against solid tumors; evaluated in Phase I/Phase 1b trials.
Oral immune‑activating small‑molecule candidate (preclinical / IND‑enabling)
An orally available small molecule designed to activate anti‑tumor immune responses in solid tumors; lead candidate selected for IND‑enabling studies and shown active in preclinical tumor models.
Tumor‑associated cell therapy candidate (preclinical)
A cell therapy approach designed to activate tumor‑infiltrating lymphocytes for treatment of specific indications (preclinical development).
Cell therapy delivery platform using RNA interference
A delivery and cell‑processing platform that uses RNAi approaches to modulate immune checkpoints in patient cells, intended to broaden applicability of cell therapy approaches.
Autologous cell therapy product targeting Cbl‑b (clinical-stage)
An autologous peripheral blood cell therapy in which immune cells are modified to silence the checkpoint regulator Cbl‑b, intended to activate patient immune responses against solid tumors; evaluated in Phase I/Phase 1b trials.
Oral immune‑activating small‑molecule candidate (preclinical / IND‑enabling)
An orally available small molecule designed to activate anti‑tumor immune responses in solid tumors; lead candidate selected for IND‑enabling studies and shown active in preclinical tumor models.
Tumor‑associated cell therapy candidate (preclinical)
A cell therapy approach designed to activate tumor‑infiltrating lymphocytes for treatment of specific indications (preclinical development).
Cell therapy delivery platform using RNA interference
A delivery and cell‑processing platform that uses RNAi approaches to modulate immune checkpoints in patient cells, intended to broaden applicability of cell therapy approaches.
Services
Preclinical study partnerships
Structured collaboration with academic or clinical research groups to perform preclinical evaluation of candidates in tumor models.
Clinical trial execution and management (Phase I / Phase 1b)
Design, regulatory approval, multi‑center trial setup, patient recruitment and trial conduct for early‑phase studies in advanced solid tumors.
GMP manufacturing and rapid cell processing services
Production of clinical‑grade autologous cell therapy products at GMP sites, including expedited workflows to prepare and release patient doses rapidly.
IND‑enabling study execution and regulatory preparation
Conduct of preclinical safety and efficacy studies required for IND submissions and preparation of regulatory documentation to enable clinical entry.
Scientific data generation and conference presentations
Preparation of clinical and preclinical data for presentation at scientific meetings and investor events.
Preclinical study partnerships
Structured collaboration with academic or clinical research groups to perform preclinical evaluation of candidates in tumor models.
Clinical trial execution and management (Phase I / Phase 1b)
Design, regulatory approval, multi‑center trial setup, patient recruitment and trial conduct for early‑phase studies in advanced solid tumors.
GMP manufacturing and rapid cell processing services
Production of clinical‑grade autologous cell therapy products at GMP sites, including expedited workflows to prepare and release patient doses rapidly.
IND‑enabling study execution and regulatory preparation
Conduct of preclinical safety and efficacy studies required for IND submissions and preparation of regulatory documentation to enable clinical entry.
Scientific data generation and conference presentations
Preparation of clinical and preclinical data for presentation at scientific meetings and investor events.
Expertise Areas
- Cell therapy development (autologous PBMC approaches)
- Small‑molecule immuno‑oncology discovery
- Preclinical tumor-model efficacy testing
- Early‑phase clinical trial management (Phase I/1b)
Key Technologies
- RNA interference (RNAi) for cell modification
- Autologous PBMC modification
- Immune‑checkpoint modulation (Cbl‑b and related pathways)
- Orally available immune‑activating small molecules